Antipsychotic drugs and safety concerns for breast-feeding infants

Tapan Parikh, Dharmendra Goyal, Jonathan R. Scarff, Steven Lippmann*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Antipsychotic drugs prescribed to treat psychiatric symptoms during the postpartumperiod are secreted into breastmilk. Because breast-feeding is crucial to infant development, it is important to select a medication that poses the fewest adverse consequences. Aripiprazole, haloperidol, perphenazine, and trifluoperazine demonstrate no known developmental dangers. Olanzapine, quetiapine, and risperidone are cited as safe, although monitoring is recommended. Chlorpromazine and clozapine may induce developmental concerns. There are limited safety data for asenapine, fluphenazine, iloperidone, loxapine, lurasidone, paliperidone, pimozide, thioridazine, thiothixene, and ziprasidone. Clinicians should choose medications considered to be the safest and prescribe them at the lowest effective doses

Original languageEnglish (US)
Pages (from-to)686-688
Number of pages3
JournalSouthern Medical Journal
Issue number11
StatePublished - 2014
Externally publishedYes


  • Antipsychotic drugs
  • Atypical antipsychotic medications
  • Breast-feeding
  • Lactation
  • Typical antipsychotic agents

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Antipsychotic drugs and safety concerns for breast-feeding infants'. Together they form a unique fingerprint.

Cite this